US20100137358A1
(en)
*
|
1996-11-05 |
2010-06-03 |
Dr. Reddy's Laboratories Ltd. |
Solifenacin compositions
|
FR2772378B1
(fr)
*
|
1997-12-12 |
2000-02-04 |
Synthelabo |
Derives d'imidazole, leur preparation et leur application en therapeutique
|
US7214687B2
(en)
|
1999-07-14 |
2007-05-08 |
Almirall Ag |
Quinuclidine derivatives and medicinal compositions containing the same
|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
JP2001316670A
(ja)
*
|
2000-05-02 |
2001-11-16 |
Dainippon Ink & Chem Inc |
液晶組成物
|
AP1420A
(en)
*
|
2000-06-27 |
2005-05-30 |
Salvat Lab Sa |
Carbamates derived from arylalkylamines.
|
SI1345937T1
(sl)
*
|
2000-12-22 |
2006-02-28 |
Almirall Prodesfarma Ag |
Derivati kinulidinkarbamata in njihova uporaba kot M3 antagonisti
|
CA2433128C
(en)
|
2000-12-28 |
2010-05-25 |
Almirall Prodesfarma Ag |
Novel quinuclidine derivatives and medicinal compositions containing the same
|
AU2002315814B2
(en)
|
2001-07-10 |
2007-05-31 |
Astellas Pharma Inc. |
Medicinal composition for treatment of interstitial cystitis
|
US7452904B2
(en)
*
|
2001-12-20 |
2008-11-18 |
Chiesi Farmaceutici S.P.A. |
1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists
|
EP1552825A4
(en)
*
|
2002-06-07 |
2009-11-25 |
Astellas Pharma Inc |
THERAPEUTIC AGENT FOR THE TREATMENT OF VESIC HYPERACTIVITY
|
ES2203327B1
(es)
|
2002-06-21 |
2005-06-16 |
Almirall Prodesfarma, S.A. |
Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
|
ES2204295B1
(es)
|
2002-07-02 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de quinuclidina-amida.
|
CA2492121A1
(en)
|
2002-07-08 |
2004-01-15 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
WO2004014853A1
(en)
|
2002-07-31 |
2004-02-19 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
|
AU2002321711A1
(en)
|
2002-08-09 |
2004-02-25 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
|
US7288562B2
(en)
|
2002-08-23 |
2007-10-30 |
Ranbaxy Laboratories Limited |
Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
|
MXPA05003398A
(es)
*
|
2002-10-29 |
2005-06-22 |
Pharmacia & Upjohn Co Llc |
Compuestos de amonio cuaternario.
|
JP2006518707A
(ja)
|
2002-12-10 |
2006-08-17 |
ランバクシー ラボラトリーズ リミテッド |
ムスカリン様受容体アンタゴニストとしての3,6−二置換アザビシクロ[3.1.0]ヘキサン誘導体
|
MXPA05006656A
(es)
*
|
2002-12-20 |
2006-02-22 |
Dynogen Pharmaceuticals Inc |
Metodos de tratamiento de desordenes de vejiga no dolorosos usando moduladores del canal de calcio subunidad (2o.
|
AU2002347553A1
(en)
*
|
2002-12-23 |
2004-07-14 |
Ranbaxy Laboratories Limited |
Flavaxate derivatives as muscarinic receptor antagonists
|
AU2002347552A1
(en)
|
2002-12-23 |
2004-07-14 |
Ranbaxy Laboratories Limited |
1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
|
US7488748B2
(en)
|
2003-01-28 |
2009-02-10 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
US20040198822A1
(en)
*
|
2003-03-21 |
2004-10-07 |
Dynogen Pharmacueticals, Inc. |
Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
|
US7517905B2
(en)
|
2003-04-09 |
2009-04-14 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
JP2006514978A
(ja)
|
2003-04-10 |
2006-05-18 |
ランバクシー ラボラトリーズ リミテッド |
ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
|
US7560479B2
(en)
|
2003-04-10 |
2009-07-14 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
BRPI0409302A
(pt)
|
2003-04-11 |
2006-04-11 |
Ranbaxy Lab Ltd |
derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
|
WO2004091597A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Pharmacia & Upjohn Company Llc |
Method of treating irritable bowel syndrome (ibs)
|
US20050175689A1
(en)
*
|
2003-10-27 |
2005-08-11 |
Yamanouchi Pharmaceutical Co., Ltd. |
Coated fine particles containing drug for intrabuccally fast disintegrating tablet
|
CA2558877A1
(en)
*
|
2004-02-09 |
2005-08-18 |
Astellas Pharma Inc. |
Solifenacin succinate-containing composition
|
WO2005077364A1
(ja)
*
|
2004-02-18 |
2005-08-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
|
CA2560080A1
(en)
*
|
2004-03-16 |
2005-09-22 |
Astellas Pharma Inc. |
Solifenacin-containing composition
|
JPWO2005087231A1
(ja)
*
|
2004-03-16 |
2008-01-24 |
アステラス製薬株式会社 |
ソリフェナシン含有組成物
|
CN101601673B
(zh)
*
|
2004-03-25 |
2012-07-18 |
安斯泰来制药株式会社 |
用于固体制剂的索非那新或其盐的组合物
|
CZ23088U1
(cs)
|
2004-03-25 |
2011-12-19 |
Astellas Pharma Inc. |
Kompozice pevného farmaceutického prípravku solifenacinu nebo jeho soli
|
WO2006035280A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Ranbaxy Laboratories Limited |
3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
|
US20090105221A1
(en)
*
|
2004-09-29 |
2009-04-23 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
SK6196Y1
(sk)
*
|
2004-12-27 |
2012-08-06 |
Astellas Pharma Inc |
Stable particulate pharmaceutical composition of solifenacin or its salt, mixture for its preparation and tablet comprising same
|
AU2005320672B2
(en)
*
|
2004-12-27 |
2011-01-06 |
Astellas Pharma Inc. |
Stable particulate pharmaceutical composition of solifenacin or salt thereof
|
US20090131469A1
(en)
*
|
2005-02-25 |
2009-05-21 |
Astellas Pharma Inc. |
Pharmaceutical agent comprising solifenacin
|
JP3701964B1
(ja)
*
|
2005-03-08 |
2005-10-05 |
アステラス製薬株式会社 |
キヌクリジン誘導体の新規な塩
|
US20080255188A1
(en)
*
|
2005-07-11 |
2008-10-16 |
Naresh Kumar |
Muscarinic Receptor Antagonists
|
US7815939B2
(en)
|
2005-07-20 |
2010-10-19 |
Astellas Pharma Inc. |
Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
|
CA2626612A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
CA2630846A1
(en)
*
|
2005-12-21 |
2007-07-05 |
Teva Pharmaceutical Industries Ltd. |
Intermediates for preparing solifenacin
|
CZ300699B6
(cs)
*
|
2006-06-21 |
2009-07-22 |
Zentiva, A. S. |
Zpusob prípravy solifenacinu
|
WO2008011462A2
(en)
*
|
2006-07-19 |
2008-01-24 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing solifenacin and its salts
|
ES2298049B1
(es)
*
|
2006-07-21 |
2009-10-20 |
Laboratorios Almirall S.A. |
Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
|
EP2043639A2
(en)
*
|
2006-07-24 |
2009-04-08 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing polymorphic forms of solifenacin succinate
|
EP1943248A2
(en)
*
|
2006-08-03 |
2008-07-16 |
Teva Pharmaceutical Industries Ltd. |
Solifenacin base forms and preparation thereof
|
TW200825084A
(en)
*
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
WO2008062282A2
(en)
*
|
2006-11-22 |
2008-05-29 |
Medichem S.A. |
An improved process for the synthesis of solifenacin
|
CZ300692B6
(cs)
*
|
2006-12-22 |
2009-07-15 |
Zentiva, A. S. |
Zpusob prípravy solifenacinu
|
WO2008120080A2
(en)
*
|
2007-03-30 |
2008-10-09 |
Medichem, S.A. |
An improved process for the synthesis of solifenacin
|
EP2146693A2
(en)
*
|
2007-04-11 |
2010-01-27 |
Dr. Reddy's Laboratories Ltd. |
Solifenacin compositions
|
JP2009538362A
(ja)
*
|
2007-07-13 |
2009-11-05 |
テバ ファーマシューティカル インダストリーズ リミティド |
ソリフェナシンの調製方法
|
EP2172201A4
(en)
|
2007-07-20 |
2011-07-06 |
Astellas Pharma Inc |
PHARMACEUTICAL COMPOSITION FOR THE REDUCTION OF LOWER HARNESS SYMPTOMS RELATED TO PROSTATE GAL
|
EP2018850A1
(en)
*
|
2007-07-24 |
2009-01-28 |
Ratiopharm GmbH |
Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
|
SI2216021T1
(sl)
|
2007-11-02 |
2013-01-31 |
Astellas Pharma Inc. |
Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
|
WO2009073203A1
(en)
*
|
2007-12-04 |
2009-06-11 |
Amgen Inc. |
Trp-m8 receptor ligands and their use in treatments
|
JP2011505416A
(ja)
*
|
2007-12-04 |
2011-02-24 |
カディラ ヘルスケア リミティド |
化学的及びキラル的に純粋なソリフェナシン塩基及びその塩を調製する方法
|
ITMI20080195A1
(it)
|
2008-02-08 |
2009-08-09 |
Dipharma Francis Srl |
Procedimento per la preparazione di solifenacin
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
MX344177B
(es)
|
2008-03-27 |
2016-12-08 |
Chase Pharmaceuticals Corp |
Uso y composicion para tratar la demencia.
|
PL385264A1
(pl)
|
2008-05-23 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
|
PL385265A1
(pl)
|
2008-05-23 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
|
SI3067353T1
(en)
*
|
2008-07-29 |
2018-03-30 |
Krka, D.D., Novo Mesto |
Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms
|
EP2181707A1
(en)
|
2008-11-04 |
2010-05-05 |
Astellas Ireland Co., Ltd. |
Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
|
DK2394648T3
(da)
*
|
2009-02-04 |
2016-09-26 |
Astellas Pharma Inc |
Farmaceutisk sammensætning til oral indgivelse
|
EP2406257B1
(en)
|
2009-03-09 |
2019-08-07 |
Megafine Pharma (P) Ltd. |
A new method for the preparation of solifenacin and new intermediate thereof
|
JP4816828B2
(ja)
*
|
2009-03-30 |
2011-11-16 |
アステラス製薬株式会社 |
ソリフェナシン非晶質体を含有した固形医薬組成物
|
WO2011048607A1
(en)
*
|
2009-09-25 |
2011-04-28 |
Cadila Healthcare Limited |
Processes for the preparation of solifenacin or a salt thereof
|
PL234208B1
(pl)
|
2010-01-18 |
2020-01-31 |
Zakl Farmaceutyczne Polpharma Spolka Akcyjna |
Sposób wytwarzania bursztynianu solifenacyny
|
WO2011125763A1
(ja)
|
2010-03-31 |
2011-10-13 |
小野薬品工業株式会社 |
手足症候群の予防および/または治療剤
|
AU2011245499B2
(en)
|
2010-04-30 |
2014-09-25 |
Merck Sharp & Dohme Corp. |
Novel beta 3 adrenergic receptor agonists
|
US9918970B2
(en)
|
2010-05-19 |
2018-03-20 |
Astellas Pharma Inc. |
Pharmaceutical composition comprising solifenacin
|
US8772491B2
(en)
|
2010-06-28 |
2014-07-08 |
Aurobindo Pharma Ltd |
Process for the preparation of solifenacin succinate
|
EP2590973B1
(en)
|
2010-07-05 |
2016-08-31 |
Crystal Pharma, S.A.U. |
Solifenacin salts
|
EP2638039A1
(de)
|
2010-11-11 |
2013-09-18 |
Hexal AG |
Kristallines solifenacin-succinat
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
KR20140044816A
(ko)
|
2011-05-10 |
2014-04-15 |
테라비다, 인코포레이티드 |
과민성 방광을 치료하기 위한 솔리페나신과 타액 자극제의 복합제
|
WO2012175119A1
(en)
|
2011-06-22 |
2012-12-27 |
Isochem |
Process for the preparation of solifenacin and salts thereof
|
KR101365849B1
(ko)
|
2012-03-28 |
2014-02-24 |
경동제약 주식회사 |
솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
|
WO2014005601A1
(en)
|
2012-07-02 |
2014-01-09 |
Pharmathen S.A. |
A process for the preparation of solifenacin or a salt thereof
|
US20150306090A1
(en)
|
2012-08-31 |
2015-10-29 |
Astellas Pharma Inc. |
Orally administered medical composition
|
EA038489B1
(ru)
|
2012-09-05 |
2021-09-06 |
Чейс Фамасьютикалз Корпорейшн |
Антихолинэргическая нейропротективная композиция и способы
|
CN103787969B
(zh)
|
2012-10-30 |
2016-07-06 |
上海京新生物医药有限公司 |
一种(1s)-1-苯基-3,4-二氢-2(1h)-异喹啉甲酸酯的制备方法
|
CA2893627C
(en)
*
|
2012-12-06 |
2021-09-14 |
Chiesi Farmaceutici S.P.A. |
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
|
EP2778167A1
(en)
|
2013-03-11 |
2014-09-17 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
|
RU2641285C2
(ru)
*
|
2013-07-13 |
2018-01-17 |
Бэйцзин Фсвэлкам Текнолоджи Девелопмент Ко., Лтд |
Соединения хинина, способ их получения и их медицинское применение
|
CA3193201A1
(en)
|
2014-05-06 |
2015-11-12 |
Anthony G. Visco |
Methods of treating or preventing preterm labor
|
CN104592221A
(zh)
*
|
2015-01-26 |
2015-05-06 |
中山奕安泰医药科技有限公司 |
一种合成索非那新的工艺
|
KR20160146428A
(ko)
|
2015-06-12 |
2016-12-21 |
한미정밀화학주식회사 |
솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
|
KR102148414B1
(ko)
|
2017-05-15 |
2020-08-26 |
주식회사 서울제약 |
솔리페나신을 유효성분으로 하는 구강붕해필름
|
EP3724188B1
(en)
|
2017-12-12 |
2023-06-07 |
Arkuda Therapeutics |
Progranulin modulators and methods of using the same
|
AU2020290485A1
(en)
|
2019-06-12 |
2021-12-02 |
Arkuda Therapeutics |
Progranulin modulators and methods of using the same
|
CN113200979A
(zh)
*
|
2021-04-13 |
2021-08-03 |
上海予君生物科技发展有限公司 |
一种琥珀酸索非那新的合成工艺
|